文献速递腹部技术与安全CTMR

新辅助免疫治疗局部晚期结直肠癌的影像与内镜评估

Endoscopic and imaging evaluations of neoadjuvant immunotherapy in patients with locally advanced colorectal cancer with dMMR/MSI-H or POLE/POLD1 mutation.
PubMed 文献 · Eur Radiol · 2026-05-13

本研究回顾性纳入43例dMMR/MSI-H或POLE/POLD1突变的局部晚期结直肠癌患者,评估新辅助免疫治疗后形态学改变预测病理完全缓解(pCR)的价值。结果显示形态学改变有预测价值,形态学联合内镜模型AUC为0.878,高于影像学完全缓解(rCR)的0.798(p=0.07)。pCR患者中84%存在假性残留病变,需注意鉴别免疫相关不良事件。

要点

  • 形态学改变可预测pCR,联合内镜模型AUC达0.878,优于单独rCR。
  • pCR患者中84%出现假性残留病变,避免误判为残留肿瘤。
  • 识别免疫相关不良事件影像特征,防止误诊为转移灶。

核心结论

  • 形态学改变对预测pCR有诊断价值,形态学联合内镜模型展现出良好潜力。
  • 假性残留病变和分离反应是新辅助免疫治疗中不典型但常见的反应模式。
  • 准确识别免疫相关不良事件的影像特征对避免误诊为转移性疾病至关重要。

研究设计与样本

  • 回顾性单中心研究,连续纳入43例局部晚期结直肠癌患者,接受一线新辅助免疫治疗。
  • 纳入标准为dMMR/MSI-H或POLE/POLD1突变,平均年龄53.84±14.37岁,男性23例、女性20例。
  • 以病理完全缓解(pCR)为参考标准,评估rCR、形态学改变、内镜及联合模型的诊断效能(AUC)。

关键影像表现/征象

  • pCR患者中84%(21/25)出现假性残留病变。
  • 约6.98%(3/43)患者出现分离反应。
  • 发现2例免疫治疗诱发的Trousseau综合征。

诊断标准与关键数值

  • 联合模型预测pCR的AUC为0.878,rCR为0.798,两者比较p=0.07。
  • 形态学改变单独预测pCR具有诊断价值(原文未报告具体AUC数值)。

临床应用与阅片要点

  • 阅片时需警惕pCR患者中常见的假性残留病变,避免过度诊断残留肿瘤。
  • 关注分离反应模式,可能提示个性化治疗调整。
  • 仔细识别免疫相关不良事件的影像特征,防止误判为转移灶。

局限性

  • 回顾性单中心研究,样本量较小(43例)。
  • 联合模型与单独内镜的AUC比较仅达临界统计学意义(p=0.07)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: In neoadjuvant immunotherapy, radiological assessment of pathological complete response (pCR) is frequently inaccurate, and atypical response patterns are occasionally observed. This study aims to investigate the diagnostic performance of new qualitative morphological changes for predicting pCR and to provide a comprehensive characterization of the imaging and endoscopic response patterns associated with neoadjuvant immunotherapy.

MATERIALS AND METHODS: A retrospective, single-center study was conducted to enroll consecutive patients with locally advanced colorectal cancer exhibiting dMMR/MSI-H or POLE/POLD1 mutation, who received first-line neoadjuvant immunotherapy. The diagnostic performance of the radiological complete response (rCR), morphological changes, endoscopy, and a combined model integrating morphological changes and endoscopy was assessed using the area under the receiver operating characteristic curve (AUC). Additionally, atypical response patterns and imaging features of immune-related adverse events (irAEs) were documented.

RESULTS: Forty-three patients (mean age 53.84 ± 14.37; 23 males, 20 females) were included. Of these, 25 achieved pCR. Among pCR patients, 84% (21/25) had pseudoresidual disease. The combined model had a higher AUC than rCR and morphological changes alone, with numerical superiority over endoscopy alone (0.878 vs. 0.798, p = 0.07). Approximately 6.98% (3/43) of patients exhibited dissociated responses. Two cases of immunotherapy-induced Trousseau's syndrome were identified.

CONCLUSION: Morphological changes exhibit predictive value for pCR, and the combined model further shows promising potential. Pseudoresidual disease and dissociated responses are atypical but common response patterns in neoadjuvant immunotherapy. Accurate recognition of imaging features associated with various irAEs is crucial to prevent misinterpretation as metastatic disease.

KEY POINTS: Question Assessment of pathological complete response after neoadjuvant immunotherapy for locally advanced colorectal cancer is crucial, but it cannot be identified by the current radiological criteria. Findings Morphological changes exhibit predictive value for pathological complete response, and the combined model integrating morphological changes and endoscopy further shows promising potential. Clinical relevance Radiographic complete response alone is insufficient for accurately predicting pathological complete response (pCR). Pseudoresidual disease is common in pCR. Dissociated response may guide personalized treatment. Recognizing imaging features of immune-related adverse events is critical to avoid misdiagnosis as metastatic disease.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Luo Y, Huang W, Zeng Z, et al. Endoscopic and imaging evaluations of neoadjuvant immunotherapy in patients with locally advanced colorectal cancer with dMMR/MSI-H or POLE/POLD1 mutation. Eur Radiol. 2026. PMID: 42128946. doi:10.1007/s00330-026-12602-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。